Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Salbutamol
Drug ID BADD_D02433
Description Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.[Label,A174379,A174400]
Indications and Usage Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm [FDA Label, F3265, F3268].
Marketing Status Not Available
ATC Code R03AC02; R03CC02
DrugBank ID DB01001
KEGG ID D02147
MeSH ID D000420
PubChem ID 2083
TTD Drug ID D0K5CB
NDC Product Code Not Available
Synonyms Albuterol | Salbutamol | 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol | Ventolin | Sultanol | Albuterol Sulfate | Proventil
Chemical Information
Molecular Formula C13H21NO3
CAS Registry Number 18559-94-9
SMILES CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Bone marrow failureBeta-2 adrenergic receptorP07550T52522Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypopnoea22.02.01.0210.000026%Not Available
Hypotension24.06.03.002--
Hypotonia17.05.02.002; 15.05.04.0080.000026%Not Available
Hypoxia22.02.02.0030.000024%
Infection11.01.08.002--Not Available
Inflammatory bowel disease07.08.01.0160.000090%Not Available
Influenza11.05.03.001; 22.07.02.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal obstruction07.13.01.0020.000010%Not Available
Irritability19.04.02.013; 08.01.03.011--
Irritable bowel syndrome19.24.01.003; 07.02.04.0030.000039%Not Available
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Joint stiffness15.01.02.0030.000026%Not Available
Joint swelling15.01.02.0040.000064%Not Available
Lactic acidosis14.01.01.0020.000335%Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.000026%
Leukocytosis01.02.01.0020.000052%
Lip oedema23.04.01.006; 10.01.05.004; 07.05.04.0040.000039%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.000090%Not Available
Liver disorder09.01.08.001--Not Available
Loss of consciousness17.02.04.0040.000271%Not Available
Lower respiratory tract infection11.01.09.002; 22.07.01.0020.000116%Not Available
Lung disorder22.02.07.0010.000129%Not Available
Malaise08.01.01.0030.000567%
Memory impairment19.20.01.003; 17.03.02.003--
Menorrhagia21.01.03.002--
Metabolic acidosis14.01.01.0030.000064%Not Available
Metrorrhagia21.01.01.0060.000039%Not Available
Middle insomnia19.02.01.003; 17.15.03.0030.000064%Not Available
Migraine24.03.05.003; 17.14.02.0010.000064%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 12 Pages